<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393208</url>
  </required_header>
  <id_info>
    <org_study_id>MS200084_0009</org_study_id>
    <nct_id>NCT03393208</nct_id>
  </id_info>
  <brief_title>Glucophage Immediate Release (GIR) China Bioequivalence Study</brief_title>
  <official_title>A Randomized, Open-label, 2-Way-Crossover Study Assessing the Bioequivalence Between Single Doses of 500 mg Glucophage Immediate Release (GIR) Tablets (Sino-American Shanghai Squibb Pharmaceuticals Ltd./ Manufactured in China) and 500 mg GIR Tablets (Merck Santé s.a.s. in Semoy/ Manufactured in France) Under Fed and Fasted State in Two Groups of Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the bioequivalence between single doses of glucophage immediate release
      (GIR) test tablets and GIR reference tablets under fed and fasted state in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Actual">January 10, 2018</completion_date>
  <primary_completion_date type="Actual">January 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin (GIR Tablet Active Ingredient)</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Metformin (GIR Tablet Active Ingredient)</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration of Metformin (GIR Tablet Active Ingredient)</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Half-Life (t1/2) of Metformin (GIR Tablet Active Ingredient)</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Metformin (GIR Tablet Active Ingredient)</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time tlast Extrapolated to Infinity (AUCextra) of Metformin (GIR Tablet Active Ingredient)</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (λz) of Metformin (GIR Tablet Active Ingredient)</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body Clearance (CL/f) of Metformin (GIR Tablet Active Ingredient)</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution at Steady-State After Extravascular Administration (Vss/f) of Metformin (GIR Tablet Active Ingredient)</measure>
    <time_frame>Pre-dose up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to Day 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Clinically Significant Abnormalities in Vital Signs, Laboratory Parameters, Physical Examination Findings and 12-lead Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to Day 15</time_frame>
    <description>Number of subjects with clinically significant abnormalities will be reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>First Test GIR (Fasting), Then Reference GIR (Fasting)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test GIR in fasting state in Treatment Period 1 followed by reference GIR in fasting state in Treatment Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Reference GIR (Fasting), Then Test GIR (Fasting)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference GIR in fasting state in Treatment Period 1 followed by test GIR in fasting state in Treatment Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Test GIR (Fed), Then Reference GIR (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test GIR in fed state in Treatment Period 1 followed by reference GIR in fed state in Treatment Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Reference GIR (Fed), Then Test GIR (Fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference GIR in fed state in Treatment Period 1 followed by test GIR in fed state in Treatment Period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test GIR</intervention_name>
    <description>Subject will receive 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).</description>
    <arm_group_label>First Test GIR (Fasting), Then Reference GIR (Fasting)</arm_group_label>
    <arm_group_label>First Reference GIR (Fasting), Then Test GIR (Fasting)</arm_group_label>
    <arm_group_label>First Test GIR (Fed), Then Reference GIR (Fed)</arm_group_label>
    <arm_group_label>First Reference GIR (Fed), Then Test GIR (Fed)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference GIR</intervention_name>
    <description>Subject will receive 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).</description>
    <arm_group_label>First Test GIR (Fasting), Then Reference GIR (Fasting)</arm_group_label>
    <arm_group_label>First Reference GIR (Fasting), Then Test GIR (Fasting)</arm_group_label>
    <arm_group_label>First Test GIR (Fed), Then Reference GIR (Fed)</arm_group_label>
    <arm_group_label>First Reference GIR (Fed), Then Test GIR (Fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has given written informed consent before any trial-related activities

          -  Chinese male and female subjects (at least 1/4 of each gender per trial group)

          -  Age between 18 and 55 years, inclusive

          -  Weight: 50 to 80 kilogram (kg); Body mass index (BMI): 18 to 30 kg per meter square

          -  Nonsmoker since at least 3 months

          -  Good physical and mental health status, determined on the basis of the medical history
             and a physical examination

          -  All values for biochemistry and hematology tests of blood and urine within the normal
             range or showing no clinically relevant deviation as judged by the Investigator

          -  Electrocardiogram recording (12-lead ECG) without signs of clinically relevant
             pathology as judged by the Investigator

          -  Vital signs (blood pressure, pulse, body temperature, and respiration) in sitting
             position within the normal range or showing no clinically relevant deviation as judged
             by the Investigator

          -  All women of childbearing potential (WOCBP) are not nursing, are not pregnant, and are
             using highly effective methods of birth control

          -  Negative screen for alcohol and drugs of abuse (cannabis, benzodiazepines,
             barbiturates, opiates, cocaine, and methyl amphetamine) at screening and on admission

          -  Negative screen for hepatitis A virus (HAV) antibodies, hepatitis B surface antigen
             (HBsAg), hepatitis C virus (HCV) antibodies, human immunodeficiency virus (HIV)
             antibodies, and Treponema pallidum (TP) antibodies

        Exclusion Criteria:

          -  Participation in a clinical trial within 90 days prior to first drug administration

          -  Blood donation (equal or more than 500 milliliter [mL]) or significant blood loss
             within 90 days prior to first drug administration

          -  Any surgical or medical condition, including findings in the medical history or in the
             pretrial assessments, or any other significant disease, that in the opinion of the
             Investigator, constitutes a risk or a contraindication for the participation of the
             subject in the trial or that could interfere with the trial objectives, conduct or
             evaluation

          -  History of surgery of the gastrointestinal tract which could influence the
             gastrointestinal absorption and/or motility according to the Investigator's opinion

          -  History or presence of relevant liver diseases or hepatic dysfunction Allergy:
             ascertained or presumptive hypersensitivity to the active drug substance and/or
             formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in
             general, which the Investigator considers may affect the outcome of the trial

          -  Receipt of any prescription or nonprescription medication within 2 weeks before the
             first IMP administration, including multivitamins and herbal products (example, St
             John's Wort, or traditional Chinese medicines), except paracetamol

          -  Renal failure or renal dysfunction (creatinine clearance &lt; 80 mL/minute) as assessed
             by using the estimated measure with the Modification of Diet in Renal Disease (MDRD)
             equation

          -  Known lack of subject compliance or inability to communicate or cooperate with the
             Investigator (example, language problem and poor mental status)

          -  Nonacceptance of trial high-fat breakfast (example, vegetarians, vegans, and subjects
             who follow special diets)

          -  Consumption of large quantities of methyl xanthine-containing beverages (&gt; 5 cups of
             coffee/day or equivalent)

          -  Consumption of grapefruit, cranberry or juices of these fruits, from 14 days prior to
             drug administration until collection of the last pharmacokinetic sample in Period 2

          -  Any contraindication to Glucophage

          -  Abnormal and clinically significant chest X-ray finding at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Glucophage Immediate Release (GIR)</keyword>
  <keyword>Bioequivalence Study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

